FDA Inspection
Sparsha Pharma Usa IncSparsha Pharma Usa Inc – FDA Inspection, Sep 4, 2025
Record Details
This FDA Inspection record concerns Sparsha Pharma Usa Inc, with an inspection on September 4, 2025, issued by the Los Angeles District Office, covering human drugs.
View Company Profile
ID · 4c28f907-5cd5-405c-a8ca-e5fbd00313fb
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1280450
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
10- 21 CFR 211.160(a)Lab controls established, including changes
- 21 CFR 211.165(e)Test methods
- 21 CFR 820.20(b)Lack of or inadequate organizational structure
- 21 CFR 820.100(b)Documentation
- 21 CFR 211.142Written warehousing procedures established/followed
- 21 CFR 211.68(b)Computer control of master formula records
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.160(b)(2)Acceptance of in-process materials
- 21 CFR 211.194(a)Complete test data included in records
- 21 CFR 211.188(b)(7)Documentation of Actual Yield and Theoretical Yield
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Sparsha Pharma Usa Inc
2| Date | Classification | Office | Project area |
|---|---|---|---|
| September 3, 2026 | Not classified | Los Angeles District Office | Generic Drug Evaluation |
| April 28, 2017 | OAI | Center for Devices and Radiological Health | Compliance: Devices |
Other documents for Sparsha Pharma Usa Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.